Billy Evans 的激光诊断初创公司 Haemanthus 面临审查

本文如何被排名

Signal score

16 / 100

Composite score across the factors below. Higher = stronger signal that this story matters right now.

Newsworthiness bucket

Tool

文章讨论了一家拥有专利和投资者但没有产品的初创公司，并将其与 Theranos 相提并论。

Source corroboration

Single-source cluster

Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.

Topics

product, funding

Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.

AI-industry relevance

High

Clearly on-topic for AI-industry coverage.

Story freshness

Breaking (< 6h)

Fresh story with cross-source coverage still developing. Ranking may shift as more sources report.

完整方法见我们的编辑标准。